Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis

Cover Page


Cite item

Full Text

Abstract

Treatment of psoriasis and psoriatic arthritis, especially moderate and severe, represents difficulties. Recently, various methods of molecular medicine have been actively developed, however, targeted therapy deserves special attention, which consists of chemical agents that have specific target as a specific protein or enzyme. Targeted therapy is a promising direction in many branches of medicine, especially in dermatology.

Despite the wide range of biological products, their use may be accompanied by an increased risk of infectious processes and malignant neoplasms, which makes the search for a new pharmacological solution in targeted therapy even more relevant.

This review presents the possibilities and prospects for the therapeutic use of the phosphodiesterase-4 inhibitor from the group of small molecules — apremilast, primarily in the treatment of psoriasis and psoriatic arthritis.

About the authors

O. Yu. Olisova

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Author for correspondence.
Email: olisovaolga@mail.ru
Olga Yu. Olisova — Dr. Sci. (Med.), Prof., Head of the Department of Skin and Venereal Diseases Россия

D. A. Svistunova

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Email: svistunova.dariya@icloud.com
Darya A. Svistunova — PhD Researcher, Department of Skin and Venereal Diseases Россия

L. M. Chernyavskaya

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Email: lidiache.m@yandex.ru
Lydia M. Chernyavskaya — Medical Resident, Department of Skin and Venereal Diseases Россия

E. M. Anpilogova

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Email: truelass@hotmail.com
Ekaterina M. Anpilogova — Medical Resident, Department of Skin and Venereal Diseases Россия

References

  1. Spadaccini M., D’Alessio S., Peyrin-Biroulet L., Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. International Journal of Molecular Sciences. 2017;18(6):1276. doi: 10.3390/ijms18061276
  2. Zhang Z., Fan W., Yang G., Xu Z., Wang J., Cheng Q. et al. Risk of tuberculosis in patients treated with TNF-a antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017 Mar 22;7(3):e012567.
  3. Kim J., Krueger J. G. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015 Jan;33(1):13–23.
  4. Garcet S., Nograles K., Correa da Rosa J., Schafer P. H., Krueger J. G. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. Journal of Allergy and Clinical Immunology. 2018. doi: 10.1016/j.jaci.2018.05.039
  5. Afra Т. Р., Razmi M., Dogra S. Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule. Indian Dermatol Online J. 2019 Jan-Feb;10(1):1–12.
  6. Pincelli C., Schafer P. H., French L. E., Augustin M., Krueger J. G. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. J Drugs Dermatol. 2018 Aug 1;17(8):835–840.
  7. Li H., Zuo J., Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology. 2018;9. doi: 10.3389/fphar.2018.01048
  8. Dorokhov V. S., Golovanov I. S., Tartakovsky V. A., Sukhorukov A. Y., Ioffe S. L. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors. Organic & Biomolecular Chemistry. 2018. doi: 10.1039/c8ob01039k
  9. Bakulev A. L. Signaling Pathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis. Vestnik Dermatologii i Venerologii. 2017;(5):89–96. doi: 10.25208/0042- 4609-2017-93-5-89-96
  10. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun15;83(12);1583– 1590. Epub 2012 Jan 10.
  11. Ighani A., Yu A. M., Sandhu V. K., Barankin B., Manolson M. F. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users. J Cutan Med Surg. 2019 Mar/Apr;23(2):148–156. doi: 10.1177/1203475418808764. Epub 2019 Feb 25.
  12. Knuckles M. L. F., Levi E., Soung J. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast. J Dermatolog Treat. 2018 Nov 26:1–5. doi: 10.1080/09546634.2018.1528326
  13. Radi G., Campanati A., Diotallevi F., Molinelli E., Offidani A. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting. G Ital Dermatol Venereol. 2019 Apr;154(2):166– 169. doi: 10.23736/S0392-0488.18.06095-9. Epub 2018 Sep 18.
  14. Reich K., Gooderham M., Bewley A., Green L., Soung J., Petric R. et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397–402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.
  15. Ighani A., Georgakopoulos J. R., Zhou L. L., Walsh S., Shear N., Yeung J. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. Journal of Cutaneous Medicine and Surgery. 2018;22(3):290–296. doi: 10.1177/1203475418755982
  16. Iragorri N., Hofmeister M., Spackman E., Hazlewood G. S. The Effect of Biologic and Targeted Synthetic Drugs on Work- and Productivity-related Outcomes for Patients with Psoriatic Arthritis: A Systematic Review. The Journal of Rheumatology. 2018;45(8):1124–1130. doi: 10.3899/jrheum.170874
  17. Gladman D. D., Kavanaugh A., Gómez-Reino J. J., Wollenhaupt J., Cutolo M., Schett G. et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. DOI: 10.1136/ rmdopen-2018-000669. eCollection 2018.
  18. McClanahan D. R., English J. C. 3rd. Therapeutics for Adult Nail Psoriasis and Nail Lichen Planus: A Guide for Clinicians. Am J Clin Dermatol. 2018 Aug;19(4):559–584. doi: 10.1007/s40257-018-0350-0
  19. Papp K., Reich K., Leonardi C.L. et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, con- trolled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
  20. Paul C., Cather J., Gooderham M. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
  21. Muñoz-Santos C., Sola-Ortigosa J., Guilabert A. Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment. Clinical and Experimental Dermatology. 2018;43(5):606–607. doi: 10.1111/ced.13411
  22. Ighani A., Georgakopoulos J. R., Shear N. H., Walsh S., Yeung J. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. J Am Acad Dermatol. 2018 Nov;79(5):953–956. doi: 10.1016/j.jaad.2018.04.043. Epub 2018 May 4.
  23. Sasaki J. L., Zhu T. H., Austin A., Nakamura M., Koo J. Apremilast and Cyclosporine Combination Therapy for a Patient with Both Psoriasis and Psoriatic Arthritis: A Case Report. Journal of Psoriasis and Psoriatic Arthritis. 2016;1(2).
  24. AbuHilal M., Walsh S., Shear N. Use of Apremilast in Combination with Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study. J Cutan Med Surg. 2016 Jul;20(4):313–316. doi: 10.1177/1203475416631328. Epub 2016 Feb 4.
  25. Liu Y., Zhou S., Nissel J., Wu A., Lau H., Palmisano M. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clinical Pharmacology in Drug Development. 2014;3(6):456–465. doi: 10.1002/cpdd.109
  26. Danesh M.J., Beroukhim K., Nguyen C., Levin E., Koo J. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015 Jun 16;21(6). PII: 13030/qt5gf406zs
  27. Rothstein B.E., McQuade B., Greb J.E., Goldminz A.M., Gottlieb A.B. Apremilast and Secukinumab Combined Therapy in a Patient with Recalcitrant Plaque Psoriasis. J Drugs Dermatol. 2016 May 1;15(5):648–649.
  28. Galluzzo M., D’Adamio S., Campione E., Bianchi L., Talamonti M. Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. Molecular Diagnosis & Therapy. 2018 Dec;22(6):717–721.
  29. Calzavara-Pinton P. G., Sala R., Arisi M., Rossi M. T., Venturini M., Ortel B. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Br J Dermatol. 2013 Jul;169(1):130–136. doi: 10.1111/bjd.12277
  30. Bagel J., Nelson E., Keegan B. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to Severe Plaque Psoriasis. J Drugs Dermatol. 2017 Oct 1;16(10):957–962.
  31. Metyas S., Tomassian C., Messiah R., Gettas T., Chen C., Quismorio A. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Curr Rheumatol Rev. 2018 Nov 29. doi: 10.2174/1573397115666181130094455
  32. Song G. G., Lee Y. H. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2019 Feb 26. doi: 10.1007/s40261-019-00765-w
  33. Hussar D. A., Yenner S. Apremilast, albiglutide, and empagliflozin. Journal of the American Pharmacists Association. 2014;54(5):562–567. doi: 10.1331/japha.2014.14533
  34. Liu Y., Zhou S., Wan Y., Wu A., Palmisano M. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. Br J Clin Pharmacol. 2014 Nov;78(5):1050–1057. doi: 10.1111/bcp.12448
  35. Hajar T., Gontijo J. R. V., Hanifin J. M. New and developing therapies for atopic dermatitis. An Bras Dermatol. 2018 Jan-Feb;93(1):104–107. doi: 10.1590/abd1806-4841.20187682
  36. Abrouk M., Farahnik B., Zhu T. H., Nakamura M., Singh R., Lee K. et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017;77:177–180.
  37. Lacour J.-P. L’atuel et le futur du traitement de la dermatiteatipique de l’adulte. Annales de Dermatologie et de Vénéréologie. 2017;144:VS29– VS37. doi: 10.1016/s0151-9638(18)30089-9
  38. Mobasher P., Heydari Seradj M., Raffi J., Juhasz M., Atanaskova Mesinkovska N. Oral small molecules for the treatment of atopic dermatitis: a systematic review. Journal of Dermatological Treatment. 2018:1–8. doi: 10.1080/09546634.2018.1544412
  39. Lauffer F., Ring J. Target-oriented therapy: Emerging drugs for atopic dermatitis. Expert Opinion on Emerging Drugs. 2016;21(1):81–89. doi: 10.1517/14728214.2016.1146681
  40. Adamo S., Nilsson J., Krebs A., Steiner U., Cozzio A., French L. E. et al. Successful treatment of SAPHO syndrome with apremilast. British Journal of Dermatology. 2018. doi: 10.1111/bjd.16071
  41. Chen W., Wang J., Xu Z., Huang F., Qian W., Ma J. et al. Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation. Send to Front Immunol. 2018 Jul 18;9:1662. DOI: 10.3389/ fimmu.2018.01662. eCollection 2018.
  42. Castela E., Tulic M. K., Rozières A., Bourrat E., Nicolas J. F., Kanitakis J. et al. Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment. Br J Dermatol. 2019 Feb;180(2):357–364. doi: 10.1111/bjd.16897. Epub 2018 Dec 2.
  43. Waki Y., Kamiya K., Komine M., Maekawa T., Murata S., Ishii N. et al. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast. Eur J Dermatol. 2018 Jun 1;28(3):413– 414. doi: 10.1684/ejd.2018.3280
  44. Cho M., Honda T., Ueshima C., Kataoka T., Otsuka A., Kabashima K. A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast. Acta Derm Venereol. 2018 Nov 5;98(10):975–976. doi: 10.2340/00015555-2995
  45. Molina-Figuera E., González-Cantero Á., Martínez-Lorenzo E., Sánchez-Moya A. I., García-Olmedo O., Gómez-Dorado B. et al. Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast. J Cutan Med Surg. 2018 Jan/Feb;22(1):104–105. doi: 10.1177/1203475417733464
  46. Pellonnet L., Beltzung F., Franck F., Rouanet J., D’incan M. A case of severe pityriasis rubra pilaris with a dramatic response to apremilast. Eur J Dermatol. 2018 Feb 1;28(1):128–129. doi: 10.1684/ejd.2017.3187
  47. Kieffer J., Le Duff F., Montaudié H., Chiaverini C., Lacour J.-P., Passeron T. Treatment of Severe Hailey-Hailey Disease with Apremilast. JAMA Dermatology. doi: 10.1001/jamadermatol.2018.2191
  48. Calleja Algarra A., Aragón Miguel R., Velasco Tamariz V., Prieto Barrios M., Andrés Lencina J. J., Vico Alonso C. et al. Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau. Australasian Journal of Dermatology. doi: 10.1111/ajd.12990
  49. De Souza A., Strober B. E., Merola J. F., Oliver S., Franks A. G. Jr. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012;11:1224–1226.
  50. Abboud J. J., Whittington A., Ahmed M., Himebaugh J. T., Wiley L. A., Haffar A. et al. Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis. Ophthalmic Plast Reconstr Surg. 2018 May/Jun;34(3):e76–e77. DOI: 10.1097/ IOP.0000000000001047
  51. Ghoreschi K., Forchhammer S. Update on the treatment of psoriasis and psoriatic arthritis — role of apremilast. Psoriasis: Targets and Therapy. 2015;117. doi: 10.2147/ptt.s69476

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Olisova O.Y., Svistunova D.A., Chernyavskaya L.M., Anpilogova E.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies